Jounce Therapeutics, a clinical-stage biotechnology company focused on cancer immunotherapies, announced a significant restructuring on February 22, 2023, reducing its workforce by approximately 57 percent. This difficult decision stems from the company's assessment that its key clinical programs, JTX-8064 and vopratelimab, require more funding and a broader scope than Jounce can pursue independently. While data from the SELECT and INNATE trials showed promise, it was not sufficient for the company to advance the programs alone. Jounce will now seek business development opportunities to potentially continue this work. The restructuring, to be substantially completed by March 31, 2023, will result in a non-recurring charge of about $11.2 million.
